A compound of Formula or a stereoisomer or tautomeric form thereof, wherein: A represents N, C or O; B represents C or N; D represents C or N; E represents C or N; Wherein if A and E are either N or C, they are optionally substituted with R 4; R 1 represents hydrogen or C 1 -C 3 alkyl; R 2 represents C 1 -C 6 alkyl, C 1 -C 3 alkyl-R 6, benzyl, or a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such C 1 -C 6 alkyl or 3-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C 1 -C 3 alkyloxy, C 1 -C 4 alkyl, OH, CN, CFH 2, CF 2 H and CF 3; Or R 1 R 2 together with the Nitrogen to which they are attached form a 5-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of of hydrogen, halogen, C 1 -C 4 alkyloxy, C 1 -C 3 alkyl, OH, CN, CFH 2, CF 2 H and CF 3; Each R 3 is independently selected from hydrogen, halo, C 1 -C 4 alkyloxy, C 1 -C 4 alkyl, OH, CN, CFH 2, CF 2 H, CF 3 or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and N; R 4 represents hydrogen, C 1 -C 4 alkyl, C 3 -C 5 cycloalkyl, -(C=O)C 1 -C 4 -alkyl, -(C=O)-C 1 -C 3 alkyloxy or in case A or E equals C, R 4 in addition can be halogen; R 5 represents hydrogen or Halogen; R 6 represents a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C 1 -C 3 alkyloxy, C 1 -C 4 alkyl, OH, CN, CFH 2, CF 2 H and CF 3; or a pharmaceutically acceptable salt or a solvate thereof. A represents N, C or O; B represents C or N; D represents C or N; E represents C or N; Wherein if A and E are either N or C, they are optionally substituted with R 4; R 1 represents hydrogen or C 1 -C 3 alkyl; R 2 represents C 1 -C 6 alkyl, C 1 -C 3 alkyl-R 6, benzyl, or a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such C 1 -C 6 alkyl or 3-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C 1 -C 3 alkyloxy, C 1 -C 4 alkyl, OH, CN, CFH 2, CF 2 H and CF 3; Or R 1 R 2 together with the Nitrogen to which they are attached form a 5-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of of hydrogen, halogen, C 1 -C 4 alkyloxy, C 1 -C 3 alkyl, OH, CN, CFH 2, CF 2 H and CF 3; Each R 3 is independently selected from hydrogen, halo, C 1 -C 4 alkyloxy, C 1 -C 4 alkyl, OH, CN, CFH 2, CF 2 H, CF 3 or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and N; R 4 represents hydrogen, C 1 -C 4 alkyl, C 3 -C 5 cycloalkyl, -(C=O)C 1 -C 4 -alkyl, -(C=O)-C 1 -C 3 alkyloxy or in case A or E equals C, R 4 in addition can be halogen; R 5 represents hydrogen or Halogen; R 6 represents a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C 1 -C 3 alkyloxy, C 1 -C 4 alkyl, OH, CN, CFH 2, CF 2 H and CF 3; or a pharmaceutically acceptable salt or a solvate thereof.